Blueprint Medicines Corporation (0HOJ.L)
0HOJ.L Stock Price Chart
Explore Blueprint Medicines Corporation interactive price chart. Choose custom timeframes to analyze 0HOJ.L price movements and trends.
0HOJ.L Company Profile
Discover essential business fundamentals and corporate details for Blueprint Medicines Corporation (0HOJ.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
682.00
CEO
Kathryn Haviland
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
0HOJ.L Financial Timeline
Browse a chronological timeline of Blueprint Medicines Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 28 Oct 2025
Upcoming earnings on 30 Jul 2025
Revenue estimate is $171.34M.
Earnings released on 1 May 2025
EPS came in at $0.01 surpassing the estimated -$0.49 by +102.06%, while revenue for the quarter reached $149.41M, missing expectations by -13.54%.
Earnings released on 13 Feb 2025
EPS came in at -$0.79 falling short of the estimated -$0.70 by -11.59%, while revenue for the quarter reached $146.37M, beating expectations by +0.82%.
Earnings released on 30 Oct 2024
EPS came in at -$0.89 surpassing the estimated -$0.96 by +7.62%, while revenue for the quarter reached $128.18M, beating expectations by +0.49%.
Earnings released on 1 Aug 2024
EPS came in at -$0.80 surpassing the estimated -$1.29 by +38.14%, while revenue for the quarter reached $138.16M, beating expectations by +32.82%.
Earnings released on 2 May 2024
EPS came in at $1.40 surpassing the estimated -$1.67 by +184.01%, while revenue for the quarter reached $96.12M, beating expectations by +18.82%.
Earnings released on 4 Mar 2024
EPS came in at -$1.82 surpassing the estimated -$2.04 by +10.69%, while revenue for the quarter reached $71.96M, beating expectations by +7.21%.
Earnings released on 26 Oct 2023
EPS came in at -$2.20 surpassing the estimated -$2.37 by +6.93%, while revenue for the quarter reached $56.57M, beating expectations by +11.66%.
Earnings released on 2 Aug 2023
EPS came in at -$2.19 surpassing the estimated -$2.52 by +12.86%, while revenue for the quarter reached $57.57M, beating expectations by +26.24%.
Earnings released on 4 May 2023
EPS came in at -$2.15 surpassing the estimated -$2.67 by +19.24%, while revenue for the quarter reached $63.29M, beating expectations by +51.23%.
Earnings released on 16 Feb 2023
EPS came in at -$2.65 surpassing the estimated -$2.65 by +0.18%, while revenue for the quarter reached $38.78M, beating expectations by +13.73%.
Earnings released on 30 Sept 2022
EPS came in at -$2.23 surpassing the estimated -$2.49 by +10.39%, while revenue for the quarter reached $65.98M, beating expectations by +51.64%.
Earnings released on 30 Jun 2022
EPS came in at -$2.68 falling short of the estimated -$2.24 by -19.63%, while revenue for the quarter reached $36.55M, missing expectations by -1.97%.
Earnings released on 31 Mar 2022
EPS came in at -$1.79 surpassing the estimated -$1.91 by +6.33%, while revenue for the quarter reached $62.73M, beating expectations by +56.47%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$5.40, while revenue for the quarter reached $107.02M.
Earnings released on 30 Sept 2021
EPS came in at -$2.00 falling short of the estimated -$0.72 by -178.81%, while revenue for the quarter reached $24.19M, missing expectations by -76.66%.
Earnings released on 30 Jun 2021
EPS came in at -$1.86, while revenue for the quarter reached $27.30M.
Earnings released on 31 Mar 2021
EPS came in at -$1.72, while revenue for the quarter reached $21.58M.
Earnings released on 31 Dec 2020
EPS came in at -$1.53, while revenue for the quarter reached $34.11M.
Earnings released on 30 Sept 2020
EPS came in at $11.16, while revenue for the quarter reached $745.12M.
0HOJ.L Stock Performance
Access detailed 0HOJ.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.